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Background: We developed and validated an automated database case definition for diabetes in children and
youth to facilitate pharmacoepidemiologic investigations of medications and the risk of diabetes.
Methods: The present study was part of an in-progress retrospective cohort study of antipsychotics and diabetes in
Tennessee Medicaid enrollees aged 6–24 years. Diabetes was identified from diabetes-related medical care
encounters: hospitalizations, outpatient visits, and filled prescriptions. The definition required either a primary
inpatient diagnosis or at least two other encounters of different types, most commonly an outpatient diagnosis
with a prescription. Type 1 diabetes was defined by insulin prescriptions with at most one oral hypoglycemic
prescription; other cases were considered type 2 diabetes. The definition was validated for cohort members in the
15 county region geographically proximate to the investigators. Medical records were reviewed and adjudicated for
cases that met the automated database definition as well as for a sample of persons with other diabetes-related
medical care encounters.
Results: The study included 64 cases that met the automated database definition. Records were adjudicated for 46
(71.9%), of which 41 (89.1%) met clinical criteria for newly diagnosed diabetes. The positive predictive value for type
1 diabetes was 80.0%. For type 2 and unspecified diabetes combined, the positive predictive value was 83.9%. The
estimated sensitivity of the definition, based on adjudication for a sample of 30 cases not meeting the automated
database definition, was 64.8%.
Conclusion: These results suggest that the automated database case definition for diabetes may be useful for
pharmacoepidemiologic studies of medications and diabetes.
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The pronounced increase in adolescents and young
adults of the incidence of type 2 diabetes [1,2] has sti-
mulated interest in the epidemiology of diabetes in this
population. Factors of interest include genetic character-
istics [3,4], diet [5,6], lifestyle [7,8], environmental fac-
tors [9], and prescribed medications [10-12]. Given that
type 2 diabetes is a chronic disease with serious health
consequences [13-15], there is an urgent need to better
understand its pathophysiology so that appropriate
preventive measures can be devised in this vulnerable
population. Although it is an important public health
problem, medication-associated type 2 diabetes occurs
infrequently. Clinical trials and prospective cohort studies
are unlikely to have sufficient power or duration of follow-
up needed to detect important inter-drug differences in
type 2 diabetes risk, and will often exclude vulnerable
populations such as children and youth.
Large automated databases of medical care encounters
are therefore a valuable resource for observational studies
of the epidemiology of medication-associated type 2
diabetes in children and youth. Database records of in-
patient and outpatient medical care encounters allow
efficient identification of newly diagnosed cases of dia-
betes for large populations. They are particularly valu-
able for studies of medications, as databases include
computerized prescription records, which provide ob-
jective, detailed, reliable and relatively low-cost mea-
sures of drug exposure [16]. Database records of
medical encounters may also allow identification of
newly diagnosed cases of type 2 diabetes. However,
these records are subject to misclassification [17,18],
including identification of existing (rather than new-
onset) diabetes, which may introduce bias that cannot
be overcome using statistical adjustment or other data
analytic techniques. A reliable computer case definition
is therefore essential for conducting studies of newly
diagnosed type 2 diabetes associated with medication
exposure using automated databases.
Thus, we utilized a sample from an in-progress retro-
spective cohort study in Tennessee Medicaid enrollees
6–24 years of age who were treated with atypical anti-
psychotic drugs or control medications to develop and
validate a case definition for newly diagnosed diabetes
suitable for automated databases.
Methods
Sources of data
The automated database case definition was part of an
in-progress retrospective cohort study of antipsychotics
and the risk of type 2 diabetes among children and youth
enrolled in Tennessee Medicaid [18]. Computerized Me-
dicaid files include an enrollment file as well as files
recording prescriptions filled at pharmacies, hospitaladmissions, outpatient visits, and long-term care resi-
dence. The Medicaid files have been augmented by link-
age with computerized death certificates [18] and, since
1998, with the State Hospital Discharge File, a compre-
hensive, statewide database of hospital discharges and
emergency department visits, which provides informa-
tion occasionally missing from Medicaid files. These files
permitted identification of both the study cohort and
the medical care encounters used to identify potential
diabetes cases [16,18].
Tennessee Medicaid is an expanded version of the
joint federal-state Medicaid program that finances med-
ical care for qualifying low income persons. Expansions
in 1994 extended Medicaid to include previously unin-
sured persons. Tennessee Medicaid enrollees had no de-
ductible, co-pay, or prescription limits for most of the
study period. In 2005, a five prescription per month limit
(of which only two prescriptions could be for brand-
name drugs) was enacted. However, this requirement did
not apply to children or youth under 21 years of age.
Furthermore, diabetes medications (insulin preparations
and oral hypoglycemics) and diabetic supplies were con-
sidered exempt (i.e., did not count toward the prescrip-
tion limit) during the entire study period, and none of
the diabetes drugs could be obtained over-the-counter.
Thus, data were considered complete for diabetes pre-
scriptions and supplies used as components of the dia-
betes computer case definition (discussed below).
Children and youth eligible for the cohort were 6 to
24 years of age and enrolled in Tennessee Medicaid at
some time between 1 January 1996 and 31 December
2007. Cohort membership also required at least one year
of prior enrollment (with respect to time zero, the first
day in which the cohort member satisfied all of the in-
clusion and exclusion criteria for a recent initiator of
study medications, as discussed below), during which
there was medical care utilization and full prescription
drug coverage (allowing lapses of ≤ 7 days), which maxi-
mized availability of data needed for study variables. The
cohort excluded persons with life-threatening illness, in-
stitutional residence, diagnosed schizophrenia or related
psychosis or other condition for which antipsychotics
are the only recommended treatment, medical care indi-
cating diabetes (including ICD-9-CM codes consistent
with a diagnosis of diabetes and/or filled prescriptions
for diabetes medications), pregnant women (because
gestational diabetes might be misdiagnosed) or women
with diagnosed polycystic ovarian syndrome (treated
with oral hypoglycemics). Cohort members could not
have been in the hospital in the past 30 days because
Medicaid files do not include in-hospital medications.
The cohort consisted of eligible recent initiators of
antipsychotics or other psychotropic drugs (mood stabi-
lizers, attention-deficit hyperactivity disorder drugs,
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pressants, benzodiazepines). Recent initiators filled a
qualifying prescription for a study drug on a day of co-
hort eligibility, with no prescription fill for a study drug
in the preceding 365 days. Cohort members could also
have non-qualifying use of study drugs in the 90 days
preceding the qualifying prescription to allow inclusion
of patients starting a study drug shortly after a hospital
discharge; however, for cohort members who filled a
study drug prescription within this 90 day window, there
had to be no filled prescriptions for study drug in the
preceding 365 days. Follow-up began on the day follow-
ing the prescription fill and ended with the end of the
study, the 25th birthday, loss of enrollment, death, failure
to meet study inclusion/exclusion criteria, or 365 days fol-
lowing the last day of current use of the study psycho-
tropic drug.
The Vanderbilt Committee for the Protection of
Human Subjects and the Tennessee Bureau of Medicaid
and Department of Health approved the study.
Automated Database Definition for Diabetes
The primary automated database case definition (Figure 1)
began with medical care encounters that indicated pos-
sible diagnosis or treatment of diabetes, termed diabetes-
related medical care encounters. These encounters couldFigure 1 Automated database case definition for diabetes mellitus. *
required when such encounters were identified from secondary inpatient I
filled prescriptions for diabetes medications (see Table 1 for complete defin
confirmation). Confirmation was needed in order to limit potential misclass
were confirmed by a subsequent prescription for diabetes medications. Me
subsequent ICD-9-CM diabetes diagnosis codes or by a subsequent diabet
management.be hospitalizations (tertiary or quaternary care settings),
outpatient visits (primary or secondary care settings), or
filled prescriptions for diabetes medications (Table 1). For
each cohort member with such an encounter, we consid-
ered the first encounter during study follow-up.
If the encounter was a hospitalization with a primary
discharge diagnosis of diabetes, the case definition was
met. However, two additional steps were required for
other types of encounters (Figure 1). First, cases with a
diagnosis of polycystic ovarian syndrome within 120 days
of the initial encounter were excluded. Polycystic ovarian
syndrome was not uncommon in the study cohort, its
symptoms overlap with those of diabetes, and it is often
treated with oral antidiabetic drugs [19]. Second, con-
firmation of the initial encounter was required. Gener-
ally, a diagnosis would be confirmed by a subsequent
prescription and a prescription by either a subsequent
diagnosis of diabetes or by a subsequent diabetes medi-
cation prescription with a procedure indicating diabetes
management (Table 1). This further confirmation was
required because a single diagnosis frequently indicated
a diagnostic workup and prescriptions in the absence of
a diagnosis often were for polycystic ovarian syndrome.
Once the criteria for the automated database case def-
inition were met, we assigned an index date. Generally,
this was the date of the initial diabetes-related medicalConfirmation of initial diabetes related medical encounters were
CD-9-CM diagnosis codes, outpatient ICD-9-CM diagnosis codes, or
itions for diabetes-related medical encounters and diabetes
ification. Medical encounters identified from ICD-9-CM diagnosis codes
dical encounters identified form prescriptions were confirmed by
es medication prescription with a procedure indicating diabetes
Table 1 Definitions for automated database algorithm to identify diabetes
Inpatient-Primary Inpatient-Secondary Outpatient† Prescription{
Diabetes-Related Medical Care Encounter*
Definition Primary discharge diagnosis
of diabetes (ICD-9-CM
codes of 250, 250.0, 250.1,
250.2, 250.3, 250.9)}
Inpatient stay with
1) a secondary or admission
diagnosis for diabetes; or
2) a physician encounter
with a primary diagnosis of
diabetes during the hospital
stay period, defined as the
day prior to admission through
the day following discharge.










There can be no diagnosis,
primary or secondary, of
polycystic ovarian




Admission date or prior
day if ED/ outpatient visit
with diabetes diagnosis
on that day
As for inpatient-primary Day of visit Day of prescription fill
Additional Criteria for Diabetes Case



























Index date, final If diabetes-related procedure# in the interval [tx-29, tx-1] tx is set to procedure date.
*Does not include deaths as there were none with diabetes coded as an underlying cause of death for cohort members during the study period.
†Includes ED visits, but excludes case management services because these may not include patient assessment. Only primary outpatient diagnoses considered
because secondary diagnoses occurred very infrequently in the absence of a primary diagnosis and a preliminary study showed they added little predictive value.
{If both a prescription and other encounter on the same day, classified as a prescription encounter. Prescriptions with a concurrent diagnosis of polycystic ovarian
syndrome were not considered as diabetes-related medical care encounters, given that this disease is frequently treated with oral hypoglycemics.
}Does not include 250.4-250.8, which are chronic complications of diabetes and thus unlikely to be present for newly diagnosed cases, particularly in a population
of children/youth.
||Period for exclusion or confirmation is [tx-120, tx + 120].
}Diabetes management: HbA1c (glycated hemoglobin), glucose test strips, glucose monitor, insulin pump.
#Diabetes-related procedure: HbA1c, islet cell antibody test, insulin RIA, or metabolic panel.
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of an earlier visit (Table 1), corresponding to the clinical
scenario in which the diagnosis was not made until after
the results of a test were available.
The automated database definition also classified diabetes
according to clinical subtype. The case was considered type
1 diabetes if there was at least one prescription for insulin
within 120 days of the index date, with no more than a sin-
gle prescription for an oral hypoglycemic in that interval.
The single prescription for an oral agent was allowed be-
cause, on occasion, these drugs may be prescribed while
awaiting the results of confirmatory testing for type 1 dia-
betes. Otherwise, the case was classified as type 2 diabetes.
The primary automated database case definition essen-
tially identified diabetes treated with pharmacotherapy. It
required both diagnosis of and treatment for diabetes, un-
less the patient was admitted to the hospital with a pri-
mary diagnosis of diabetes. In our sample, all hospitalizedcases subsequently received medications. Consequently,
the primary definition did not identify patients for whom
diabetes was managed without medications. Thus, we
also assessed a secondary automated database definition
designed to better identify such cases. This definition
(Table 1) accepted secondary inpatient diagnoses with-
out further confirmation and relaxed the requirement
for confirmation of an outpatient diagnosis with a pre-
scription, requiring only a procedure for glycosylated
hemoglobin testing (indicating diabetes management).
Medical record review sample
Medical records for a sample of diabetes-related medical
care encounters were reviewed to develop and validate the
automated database case definition. The sample was drawn
from members of the underlying cohort who had diabetes-
related medical care encounters in the 15 county region
within one travel day of Nashville. Only the first encounter
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included all encounters that met the automated database
case definition and a 60% sample of other encounters.
The cohort utilized to develop the case definition
included 172,014 members, of which 1,413 had a
diabetes-related medical care encounter (Figure 2). Of
these, 251 were in the 15 county region, of which 64
met the computer case definition and 187 did not. The
medical record review sample included all of the former
and 113 (60.4%) of the latter (Figure 2).
Adjudication procedures
For sampled diabetes-related medical care encounters,
study nurses reviewed records of all pertinent medical
care within 365 days of the index date, focusing on those
closest to the date of the diabetes-related encounter.
They collected the results of laboratory tests, interven-
tions undertaken, and, when appropriate, copies ofFigure 2 Sample for validation of automated database case
definition for diabetes mellitus. *Preliminary version of the cohort.
†Counties (State of Tennessee) included: Cannon, Cheatham,
Davidson, Dickson, Hickman, Lewis, Marshall, Maury, Montgomery,
Robertson, Rutherford, Sumner, Trousdale, Williamson, Wilson.
†Counties (State of Tennessee) included: Cannon, Cheatham,
Davidson, Dickson, Hickman, Lewis, Marshall, Maury, Montgomery,
Robertson, Rutherford, Sumner, Trousdale, Williamson, Wilson. {There
were 18 cases not adjudicated: 11--medical care provider identified,
but patient record not located (most commonly for older records);
2--medical care provider not identified in Medicaid files; 2--medical
care provider identified, but unable to visit (no longer practicing or
relocated); 3--provider refusal. }There were 83 cases not adjudicated:
45--medical care provider identified, but patient record not located
(most commonly for older records); 20--medical care provider not
identified in Medicaid files; 11--medical care provider identified, but
unable to visit (no longer practicing or relocated); 4--provider refusal
3--patient records identified but lacked sufficient information for
case adjudication.medical records. All information was redacted to conceal
patient identifying information. Each case was independ-
ently adjudicated by two investigators (WB,WC), masked
to the exposure status of the patient, with disagreements
resolved by a third reviewer (CMS).
The diagnostic criteria for diabetes required abnormal
laboratory values for glycemic indices that exceeded
standard cutoffs (Table 2) [20]. A non-fasting glucose
value of ≥ 200 mg/dL was considered diabetes, absent an
alternative recorded explanation for the elevated glucose.
The adjudication did not use results of glycosylated
hemoglobin tests, which recently have been accepted as
a standard criterion for adults [21]. Possible diabetes was
considered present if the medical record mentioned dia-
betes or hyperglycemia but there were no confirmatory
laboratory tests (Table 2). Subthreshold hyperglycemia
indicated an abnormally elevated glucose test that did
not meet the criteria for diabetes (Table 2).
Diabetes cases were further adjudicated as type 1/type
2/unspecified type. We also determined the time of first
diagnosis. Patients with a diagnosis prior to the first day
of cohort follow-up were considered prevalent cases.
Statistical methods
The positive predictive value (PPV) of the diabetes case
definition was calculated with 95% confidence intervals
(CI) for binomial proportions using Wilson’s formula.
Case confirmation from medical record review served as
the gold standard. PPV calculations were conducted
using STATA statistical software, version 11.0 (STATA
Corporation; College Station, Texas, USA).
Sensitivity of the primary automated database case def-
inition were estimated. This was expressed as a/(a + c),
where (a) was the number of true cases identified by the
definition and (c) was the number such cases that were
missed [22]. The former was estimated as the number of
cases in the catchment meeting the database definition
times its positive predictive value. The number of missed
cases was estimated as the number of diabetes-related
medical encounters not meeting computer definition
multiplied by the proportion of such cases that were true
cases (see Additional file 1: Appendix 1 for details).
Specificity of the primary automated database case
definition was also estimated. Specificity was expressed
as d/(b + d) where (d) represents the estimated number
of cases not meeting the computer case definition cor-
rectly identified as not being a diabetes case and (b)
represents the estimated number of cases meeting the
computer case definition misclassified as diabetes cases
(see Additional file 1: Appendix 1 for details).
The study was funded by a grant from the Agency for
Health Care Research and Quality, which had no role in
study conduct or reporting. The listed authors were
entirely responsible for study design, data analysis,
Table 2 Clinical criteria for diabetes, subthreshold hyperglycemia, and polycystic ovarian syndrome
1. Diabetes mellitus (DM) General criteria – any of the following:
1. Fasting plasma glucose≥ 126 mg/dL (7 mmol/L).
2. Two-hour post-prandial glucose (following 75-g glucose load)
≥ 200 mg/dL (11.1 mmol/L).
3. Signs or symptoms of diabetes mellitus (polyuria, polydipsia,
nocturia, acanthosis nigricans, weight loss, obesity/weight gain)
and random glucose≥ 200 mg/dL (11.1 mmol/L).
1.a. Type 1 DM Subtype criteria – general DM criteria (above) met, and any of the following:
1. Type 1 DM diagnosis in medical record in conjunction with at least one
of the following: (a) insulin treatment verified in medical record; (b) C-peptide
concentration≤ 0.2 nmol/L;* (c) positive islet cell (ICA) or glutamic acid
decarboxylase antibody (GADA) assay; (d) no evidence of oral antidiabetic
medication use.
2. Tentative type 1 DM diagnosis and any of the following:
(a) insulin treatment verified in medical record; (b) no evidence of oral
antidiabetic medication use.
1.b. Type 2 DM Subtype criteria –general DM criteria (above) met, and any of the following:
1. Type 2 DM diagnosis in medical record in conjunction with at least one of the following:
(a) oral antidiabetic medication treatment verified in medical record; (b) diabetes-targeted
lifestyle modification (dietary, physical activity, other weight loss) as primary diabetes treatment
verified in medical record; (c) no evidence of insulin use.
1.c. DM, unspecified General criteria for DM met (see 1. above), but case does not meet sub-type criteria for
either type 1- (see 1.a.) or type 2- (see 1.b.) DM.
2. Possible DM Possible hyperglycemia or diabetes mellitus mentioned in record, but laboratory testing
for diabetes mellitus not performed or results unknown/unavailable.
3. Subthreshold hyperglycemia Laboratory testing for diabetes performed and results available, meeting any of the following:
1. Abnormally elevated fasting plasma glucose (100–125 mg/dL).
2. Two-hour post-prandial glucose (following 75-g glucose load) 140–199 mg/dL.
3. Abnormally elevated plasma glucose level, with or without clinical signs of diabetes mellitus,
unable to verify fasting vs. non-fasting status.
4. Polycystic ovarian syndrome Any of the following:
1. Polycystic ovarian syndrome (PCOS) diagnosis documented in medical record, with or without
clinical signs and symptoms consistent with PCOS (oligomenorrhea, amenorrhea, clinical or
biochemical evidence of androgen excess, or polycystic ovaries diagnosed on ultrasonography
or other imaging procedure).
2. Tentative diagnosis of PCOS, with clinical signs and/or symptoms consistent with PCOS
(as listed above).
*Based on diagnostic criteria used by Li et al. [36] and Bruno et al. [37].
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other persons were involved. The first manuscript draft
was written by the primary and senior authors, who
vouch for the data and the analysis.Results
Adjudication status
Of the 64 diabetes-related medical care encounters that
met the primary automated database case definition, 46
(71.9%) were adjudicated (Figure 2). Fifteen of the 46
adjudicated cases satisfied the case definition of type 1
diabetes, while 31 satisfied the case definition for type 2
diabetes (Table 3). For the 76 total adjudicated cases (46
adjudicated cases that met the computer case definition;
30 adjudicated cases that did not meet the computercase definition [discussed below]), 77% were female and
the mean age was 15 years.
Of the 64 diabetes-related medication encounters that
met the case definition, 18 records could not be adjudi-
cated. The most common reason for non-adjudication
was inability to locate a medical record for the patient,
most commonly because these were older records that
had not been retained (n = 11). Other reasons for non-
adjudication included inability to identify a care provider
in the Medicaid files (n = 2), inability to obtain records
from providers that relocated or were no longer prac-
ticing (n = 2), and refusal of the provider to participate
(n = 3). Of the 113 sampled diabetes-related medical care
encounters that did not meet the case definition, 30
(26.5%) were adjudicated. For this group, 83 cases could
not be adjudicated. The primary reason for non-








Number (%) Number (%) Number (%)
Adjudicated: Total 46 (100.0) 15 (100.0) 31 (100.0)
Adjudicated: Diabetes 41 (89.1) 14 (93.3) 27 (87.1)
Type 1 13 (28.3) 12 (80.0) 1 (3.2)
Type 2 25 (54.3) 2 (13.3) 23 (74.2)
Unspecified type 3 (6.5) 0 (0.0) 3 (9.7)
Adjudicated: Not Incident Diabetes 5 (10.9) 1 (6.7) 4 (12.9)
Prevalent diabetes 1 (2.2) 1 (6.7) 0 (0.0)
Subthreshold hyperglycemia 3 (6.5) 0 (0.0) 3 (9.7)
Polycystic ovarian syndrome 1 (2.2) 0 (0.0) 1 (3.2)
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medical record (n = 45); other reasons included inability
to identify a care provider in the Medicaid files (n = 20),
inability to obtain records from providers that relocated
or were no longer practicing (n = 11), provider refusal
(n = 4), and insufficient information for case adjudication
(n = 3).Overall performance of case definition
Of the 46 adjudicated cases meeting the primary auto-
mated database definition for diabetes, 41 were adjudi-
cated as diabetes with onset beginning during cohort
follow-up (Table 3), resulting in a positive predictive
value of 89.1% (95% CI 77.0, 95.3%). The five cases not
adjudicated as diabetes included three cases of subthres-
hold hyperglycemia (Table 3; defined in Table 2), one
case of diabetes with onset before t0, and one case of
polycystic ovarian syndrome. The estimated sensitivity of
the primary automated database definition for diabetes
was 64.8% , while the specificity of the primary case
definition was > 99%.Case definition performance by diabetes subtype
We also calculated the performance of the automated
database case definition according to type of diabetes
(Table 3). Of the 41 cases meeting the case definition
adjudicated as diabetes, 13 were adjudicated as type 1,
25 were adjudicated as type 2 and for 3 the type was un-
specified. The positive predictive value of the computer
case definition for type 1 diabetes was 80.0% (95% CI
54.8, 93.0%) and that for type 2 was 74.2% (95% CI 56.8,
86.3%). When those cases for which type was unspeci-
fied were considered as type 2, the positive predictive
value of the automated database definition for type 2
was 83.9% (95% CI 67.4, 92.9%).Cases that Did Not meet diabetes case definition
Of the 30 adjudicated cases that did not meet the pri-
mary automated database case definition, 5 (16.7%) were
adjudicated as diabetes (Table 4). The other cases most
commonly were possible diabetes (Table 2), subthreshold
hyperglycemia, and polycystic ovarian syndrome (all
treated with an oral hypoglycemic). The five confirmed
cases had index diabetes-related medical care encounters
that were outpatient visits (four cases) or secondary in-
patient (one case) diagnoses; none was identified from a
filled prescription.Performance of secondary diabetes case definition
We also assessed the performance of a secondary auto-
mated database case definition designed to better iden-
tify diabetes not treated with medications (Additional
file 1: Appendix Table 1 and Additional file 1: Appendix
Table 2; Additional file 1: Appendix Figure 1). The posi-
tive predictive value of this definition was 75.9% (95% CI
63.5, 85.0%) and the estimated sensitivity was 81.1%
(95% CI 54.4, 73.9%).Discussion
We developed an algorithm to identify newly diagnosed
cases of diabetes in children and youth that utilized
automated database medical care encounter records.
The primary automated database case definition, which
generally required both diagnosis of and pharmacotherapy
for diabetes, was validated by review of medical records
with application of an objective standard for diabetes.
In the sample studied, the positive predictive value for
definite/probable diabetes was 89% and the case defin-
ition reliably distinguished between type 1 and type 2 dia-
betes. The estimated sensitivity was 65%. A secondary
definition that better captured diabetes not treated with
Table 4 Adjudication status for diabetes-related medical care encounters not meeting the automated database
definition for incident diabetes, by type of medical encounter
Inpatient, secondary diagnosis Outpatient diagnosis Filled prescription Any medical encounter type
Number (%) Number (%) Number (%) Number (%)
Adjudicated: Total 4 (100.0) 11 (100.0) 15 (100.0) 30 (100.0)
Adjudicated: Diabetes 1 (25.0) 4 (36.4) 0 (0.0) 5 (16.7)
Adjudicated: Not Diabetes 3 (75.0) 7 (63.6) 15 (100.0) 25 (83.3)
Prevalent diabetes 0 (0.0) 0 (0.0) 1 (6.7) 1 (3.3)
Possible diabetes 1 (25.0) 1 (9.1) 5 (33.3) 7 (23.3)
Subthreshold hyperglycemia 1 (25.0) 4 (36.4) 2 (13.3) 7 (23.3)
Polycystic ovarian syndrome 0 (0.0) 0 (0.0) 6 (20.0) 6 (20.0)
Laboratory test, rule-out 0 (0.0) 1 (9.1) 1 (6.7) 2 (6.7)
Miscoded diagnosis 1 (25.0) 1 (25.0) 0 (0.0) 2 (6.7)
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estimated sensitivity of 81%.
The availability of a valid computer case definition of
new-onset type 2 diabetes is crucial for conducting
pharmacoepidemiologic studies of type 2 diabetes as a
study endpoint using automated databases. Automated
databases may be the only efficient means of quantify-
ing type 2 diabetes risk associated with specific drug
exposures, given how infrequently it occurs. However,
there are several challenges to conducting pharma-
coepidemiologic studies using automated databases.
Among the most serious of these is the potential for
bias from endpoint misclassification due to coding
errors or other problems [16,17]. Most automated data-
bases, including the one used in our study, include
medical encounter and healthcare service utilization
data that were not collected specifically for research
purposes. As such, the quality of the collected data
may vary considerably [17]. In one study that used
ICD-9 diagnosis codes from one or more outpatient
records in the U.S. Indian Health Service Facility Data-
base to estimate the prevalence and incidence of dia-
betes in Navajo youth, a diagnosis of diabetes was
confirmed in less than 50% of cases [23]. The primary
reason for misclassification was coding errors.
In our study, the most common source of misclassifi-
cation was subthreshold hyperglycemia, accounting for
6% and 14% of adjudicated cases that respectively met
the primary or secondary case definitions. These cases
had an abnormal glucose laboratory value that was
below the standard cutpoint for diabetes. This may rep-
resent in part the treatment of “prediabetes” [24], an in-
creasingly common, yet controversial, trend among
adults [25]. Although such cases might reflect adverse
metabolic effects of medications, such as increased
weight, we nevertheless considered them as false posi-
tives, given that the pathophysiology of drug-induced
diabetes is incompletely understood [26].We chose positive predictive value as the primary
measure of algorithm performance based on our object-
ive to develop and validate a computer case definition to
facilitate pharmacoepidemiologic investigations of medi-
cations and the risk of new-onset diabetes. Determining
sensitivity would quantify performance of our case defin-
ition only for those already known to have new-onset
diabetes. In automated database studies, suspected (not
established) cases of new-onset diabetes would be first
identified. The positive predictive value is an ideal measure
under this circumstance, as it represents the proportion of
true cases among those identified by the computer algo-
rithm as potential cases. Our results suggest that a high
proportion of potential cases identified by our algorithm
will be true cases.
Prior studies of the association between medications
and new-onset diabetes in adults [27,28] have utilized
validated case definitions based upon both diabetes diag-
noses and prescriptions, which have been found to have
good positive predictive value [29]. However, there are
important differences for children and youth. First, type
1 diabetes has a much higher incidence. Distinguishing
type 2 diabetes, the primary concern with respect to
medication effects, must be considered for studies of
younger populations. Distinguishing between type 1 and
type 2 diabetes in the young is complicated, however, by
the ever-increasing epidemic of overweight/obesity and
other risk factors for insulin resistance in this population
[30], which may result in misdiagnosis or substantial
delays in arriving at a definitive diagnosis [31]. These
factors make it difficult to differentiate type 1 and type 2
diabetes in youth using administrative data. Administra-
tive data algorithms that rely on ICD-9 or −10 diagnosis
codes for detecting diabetes in children or youth have
been shown to capture type 1 diabetes more reliably
than type 2 diabetes cases [32,33]. Although there are
separate ICD-9-CM diagnostic codes for each type of
diabetes, we and others [33] have found these to have
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type 2 diabetes in our sample was to remove cases with
a filled prescription for insulin, in the absence of
repeated oral hypoglycemic prescriptions. Another unique
aspect of populations with large numbers of women of re-
productive age is the occurrence of polycystic ovarian syn-
drome, which, in our sample, often was indicated by a
prescription for an oral hypoglycemic without a diagnosis
of diabetes. In a recently published retrospective cohort
study of diabetes incidence in children and adolescents
that used antidiabetic drug prescriptions as a proxy for the
disease itself, 22% of children who were prescribed met-
formin received the drug for treatment of polycystic
ovarian syndrome [34].
Our primary automated database case definition fo-
cused on diabetes treated with pharmacotherapy, an im-
portant clinical consideration given that many
individuals with type 2 diabetes will be treated with life-
style interventions alone [35]. Our focus on medically-
treated diabetes may have resulted in approximately
one-third of the estimated total cases in the study sam-
ple being missed. Thus, we also assessed a secondary
definition designed to better detect diabetes that was not
treated with medications. The estimated sensitivity of
this definition improved to 81%; however, the positive
predictive value fell from 89% to 76%. The drop in the
positive predictive value was primarily due to the mis-
classification of subthreshold hyperglycemia (14% of
adjudicated cases) as diabetes.
Limitations
The automated database case definition was developed
and validated in a single sample that consisted of Tennessee
Medicaid enrollees who had recently initiated therapy
with a psychotropic medication. Although the algorithm
has face validity, over-fitting is possible. Given these
limitations, the performance of our algorithm in this co-
hort may not be generalizable to other patient popula-
tions, including Medicaid populations in other states and
in non-psychiatric populations. Further investigations in
other clinical settings and populations are needed.
We were unable to abstract and adjudicate 100% of all
records sought that met the computer case definition of
diabetes. Bias in our PPV estimate would be possible,
particularly if there were systematic differences in the
accuracy or quality of ICD-9 diagnosis coding, patterns
of clinical practice, or clinical documentation between
records that could be abstracted and those that could
not. Under these circumstances, one would be less reas-
sured that abstracted cases were representative of the
source population. We were able to abstract and adjudi-
cate nearly 72% of records for cases that met the dia-
betes computer case definition, and the most common
reason for not being able to abstract such records wasthat records were too old to be retained by the practices.
While these points provide some reassurance, we cannot
exclude completely the possibility that systematic differ-
ences between abstracted and non-abstracted cases
could have occurred, thus introducing potential bias in
our PPV estimate.
Our estimate of the sensitivity of the automated data-
base case definition relied upon adjudication of a sample
of cases with diabetes-related medical care encounters
that did not meet the database definition. We were only
able to adjudicate 27% of the potential cases in this sam-
ple. The primary reason for the low rate of adjudication
was that most of these consisted of a single prescription
or outpatient diagnosis. In this circumstance, we often
were unable to find the record for the individual patient,
most commonly because these were older records that
had not been retained in the practice. However, given
that diabetes is a chronic disease, it seems unlikely that
these isolated encounters represent true cases.
Finally, the “gold standard” for diabetes in the study
sample was based upon review of medical care provider
records. Although laboratory values were required for
adjudication of a case as diabetes [36,37], standardized
fasting glucose or glucose challenge tests were not uni-
formly obtained.Conclusion
We developed and validated an automated database case
definition for newly diagnosed diabetes. The definition
had an overall positive predictive value of 89% for defin-
ite/probable diabetes and could distinguish between type 1
and type 2 diabetes. If our findings are replicated in other
settings, our algorithm could be a useful endpoint for
pharmacoepidemiological studies that focus on the risk of
medication-associated new-onset diabetes mellitus.Additional file
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